Oppenheimer analyst Leland Gershell raised the firm’s price target on Soleno Therapeutics (SLNO) to $73 from $65 and keeps an Outperform rating on the shares. Ahead of DCCR’s anticipated late-December FDA approval for Prader-Willi syndrome, the firm has refreshed its revenue model to reflect its updated view of this patient population and product pricing. Oppenheimer now projects 2025-2029 U.S. sales of $50M, $229M, $430M, $661M, and $902M vs. prior $35M, $215M, $371M, $576M, and $795M, respectively.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics announces passing of former chairman Ernest Mario
- PepsiCo reports mixed Q3, Roblox slips after short report: Morning Buzz
- Soleno Therapeutics update on DCCR ‘a positive surprise,’ says Stifel
- Soleno says FDA sees no need for advisory committee meeting for DCCR NDA
- Soleno Therapeutics price target raised to $74 from $59 at Stifel